SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron
1
Department of Electronic and Computer Engineering, The Hong Kong University of Science and Technology, Hong Kong SAR, China
2
Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Hong Kong SAR, China
3
Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, VIC 3010, Australia
4
Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Academic Editors: Luis Martinez-Sobrido and Fernando Almazan Toral
Viruses 2022, 14(1), 79; https://doi.org/10.3390/v14010079
Received: 13 December 2021
/
Revised: 26 December 2021
/
Accepted: 31 December 2021
/
Published: 2 January 2022
(This article belongs to the Collection SARS-CoV-2 and COVID-19)
Omicron, the most recent SARS-CoV-2 variant of concern (VOC), harbours multiple mutations in the spike protein that were not observed in previous VOCs. Initial studies suggest Omicron to substantially reduce the neutralizing capability of antibodies induced from vaccines and previous infection. However, its effect on T cell responses remains to be determined. Here, we assess the effect of Omicron mutations on known T cell epitopes and report data suggesting T cell responses to remain broadly robust against this new variant.
View Full-Text
Keywords:
SARS-CoV-2; COVID-19; Omicron; variants; T cell epitopes; mutations; insertions; deletions; peptide-HLA binding
▼
Show Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
- Supplementary File 1:
ZIP-Document (ZIP, 31 KiB)
MDPI and ACS Style
Ahmed, S.F.; Quadeer, A.A.; McKay, M.R. SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron. Viruses 2022, 14, 79. https://doi.org/10.3390/v14010079
AMA Style
Ahmed SF, Quadeer AA, McKay MR. SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron. Viruses. 2022; 14(1):79. https://doi.org/10.3390/v14010079
Chicago/Turabian StyleAhmed, Syed F., Ahmed A. Quadeer, and Matthew R. McKay. 2022. "SARS-CoV-2 T Cell Responses Elicited by COVID-19 Vaccines or Infection Are Expected to Remain Robust against Omicron" Viruses 14, no. 1: 79. https://doi.org/10.3390/v14010079
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
